×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Close

If Alison depends on daily glucocorticoids, does she have glucocorticoid-induced osteoporosis (GIOP) and a high risk for fracture?

  • She recently started glucocorticoid therapy for rheumatoid arthritis (6-month course of prednisone, 10 mg/day)
  • Recently diagnosed with osteoporosis, not on therapy
  • She has no known history of fracture
  • Most recent DXA results: T-score -2.7 in total hip
  • Insurance type: Commercial

Since Hank is taking more glucocorticoid therapy, does he also have a high risk of fracture due to glucocorticoid-induced osteoporosis?

  • He recently increased his treatment for chronic obstructive pulmonary disease (COPD)
  • He started taking a daily dosage equivalent to 7.5 mg prednisone over the past 6 months
  • For osteoporosis, he takes risedronate (35 mg/week)
  • He has a history of fracture (vertebral)
  • Most recent DXA results: T-score -2.5 in lumbar spine
  • Insurance type: Medicare